Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie University Produces Research Batch Of H1N1 Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

An Australian university has produced the nation's first batch of H1N1 flu vaccine, but its 1,000 doses are available only for research purposes. The University of Queensland in Brisbane produced a liter of vaccine using a new technology that relies on the cells of insects instead of eggs. The school collaborated with U.S.-based Protein Sciences to produce the vaccine. (Click here for more

You may also be interested in...



Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

LifeSignals Plans To Market Biosensor Patch To Help Consumer Identify COVID-19 Symptoms

LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19. 

No Hiding In Social Media: More False COVID-19 Treatment Claims Found By US Agencies

FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.

UsernamePublicRestriction

Register

SC072056

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel